Has Marvin Bittner received payments from drug or device companies?

Yes. Drug and device makers reported $99,928 in general payments to Marvin Bittner across 160 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Marvin Bittner did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Marvin Bittner come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Marvin Bittner

Infectious Disease · Omaha, NENPI 1215041959

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (52.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi Pasteur Inc. accounts for 72.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2019 at $37,070 and has fallen 69.6% since, to $11,268 in 2025. Among infectious disease clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$99,928in general payments, 2019–2025

Across 160 payments — averaging $624.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi Pasteur Inc.$72K
Bavarian Nordic A/s$11K
GSK$10K
Valneva USA, Inc.$4K
Seqirus USA Inc$1K
Merck$1K
plus $169 from 3 others

What the payments were for

Consulting fees$26,31026%
Speaking & faculty fees$52,82853%
Travel & lodging$16,66217%
Food & beverage$3,2273%
Education$9011%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi Pasteur Inc.	130	$72,484
Bavarian Nordic A/s	6	$11,268
GSK	13	$9,648
Valneva USA, Inc.	5	$3,659
Seqirus USA Inc	1	$1,375
Merck	2	$1,326
Sanofi-aventis U.S. LLC	1	$75
Amgen	1	$61
Paratek Pharmaceuticals, Inc.	1	$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

FLUZONE HIGH-DOSE$45,454
FLUBLOK QUADRIVALENT$20,044
FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$14,283
MENQUADFI$11,863
SHINGRIX$8,288
FLUZONE QUADRIVALENT NORTHERN HEMISPHERE$305
NO PRODUCT DISCUSSED$103

How this compares

$99,928 in reported general payments places this provider in the 95th percentile of 55 infectious disease providers in Nebraska.

See all infectious disease providers in Nebraska →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Atovaquone-Proguanil HclAtovaquone/Proguanil Hcl	12	$865
LoperamideLoperamide Hcl	12	$92
Azithromycin	12	$36

Paid to pharmacies, not to this prescriber.

Other infectious disease in Omaha

Rudolf KotulaOmaha$221K
Mark RuppOmaha$76K
Trevor VanschooneveldOmaha$56K
Nada FadulOmaha$26K
Alison FreifeldOmaha$15K
Amir GholamiOmaha$12K
Andre KalilOmaha$11K
Kelly CawcuttOmaha$11K
Diana FlorescuOmaha$11K
Jeffrey SartinOmaha$10K

See the full list for Nebraska →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →